Cysteamine vs Hydroquinone for Melasma: What the Trials Actually Found

Short version: across the pooled reviews, the estimate favored 5% cysteamine versus placebo. The pooled reviews did not detect a statistically significant difference versus hydroquinone, which does not establish equivalence. The individual trials were small and they didn't all agree. One favored hydroquinone. One favored cysteamine over a prescription hydroquinone combination. One did not detect a statistically significant difference.

None of the studies cited here evaluated Illuminate Rx or compared its 10% formula with a 5% formula.

How are these two different?

Melasma causes brown to gray-brown patches, usually on the face. It's one form of hyperpigmentation, which just means an area of skin holding extra pigment.

Cysteamine and hydroquinone are different ingredients that both target pigment. In the trials below, cysteamine was tested at 5% whenever a strength was stated. Hydroquinone showed up as a 4% cream, a cream of unstated strength, or part of a prescription combination.

The routines differed too, which matters more than people realize. One trial left cysteamine on for 15 minutes and the hydroquinone combination on overnight. Another applied both nightly without saying whether anything was rinsed away.

Illuminate Rx is a 10% cysteamine cream. My search found no PubMed-indexed paper or ClinicalTrials.gov record through August 16, 2026 that names Illuminate Rx, tests this finished formula, or compares 10% with 5%. A higher concentration does not prove greater benefit.

What did each head-to-head trial find?

A quick note on scoring before the numbers. Melasma is measured with the Melasma Area and Severity Index (MASI), or its shorter version, the modified Melasma Area and Severity Index (mMASI). Lower is better.

The 2021 Nguyen trial did not detect a statistically significant between-group difference. Twenty people started and 14 finished, over 16 weeks, and the finishers split 5 in the cysteamine group against 9 in the hydroquinone group. Counting everyone who started, melasma scores dropped about 21% with cysteamine and about 32% with hydroquinone. The small, uneven completer groups limit interpretation. The published abstract never states either cream's strength and lists Scientis Pharma as a grant supporter.

The 2020 Brazilian trial favored hydroquinone. Forty women used either 5% cysteamine or 4% hydroquinone nightly for 120 days, and everyone used a tinted sun protection factor (SPF) 50 sunscreen. At 60 days, scores fell 24% with cysteamine and 41% with hydroquinone. At 120 days: 38% and 53%. Hydroquinone also came out ahead on the quality-of-life score. Photos showed improvement up to 74% in both groups. About the design: people were sorted by a set method rather than pure chance, and only the scorers were kept unaware of who got what. That is weaker than a full double-blind trial.

The 2020 Karrabi trial favored cysteamine. Fifty people used either 5% cysteamine for 15 minutes daily or a prescription combination cream overnight for four months. The combination contained 4% hydroquinone, retinoic acid, and a steroid. The authors reported a greater mMASI reduction with 5% cysteamine than with the prescription combination.

The two pooled reviews landed in the middle. The 2024 review combined seven trials, and its pooled estimate favored 5% cysteamine versus placebo. Against 4% hydroquinone, it did not detect a statistically significant difference. The 2026 review combined five trials and 193 patients and also did not detect a statistically significant difference for short-term use. Two of the comparison creams in that pool were hydroquinone combinations rather than plain hydroquinone, which muddies the comparison a little.

None of these discussed studies named or tested Illuminate Rx.

What "no significant difference" really means

It doesn't mean the two creams are proven equal. It means the study wasn't able to show a difference, which is a different claim.

With small groups, a real difference can hide. The 2026 review pooled 193 patients total, and its result was compatible with cysteamine being somewhat worse or somewhat better than hydroquinone. So we don't yet know. That is different from a tie.

What about side effects?

The 2026 review did not detect statistically significant differences in redness, burning, or itching between groups. The 2024 review reported more redness, irritation, burning, itching, and dryness with cysteamine than with placebo, and did not detect a statistically significant difference versus hydroquinone. The linked PubMed abstract does not report actual percentages.

The individual trials mostly agreed. The Nguyen trial said hydroquinone was better tolerated, and described the cysteamine reactions as more common but mild and reversible. The Brazilian trial reported no severe reactions in either group. The Karrabi trial called cysteamine better tolerated without giving rates.

Illuminate Rx packaging lists possible redness, dryness, skin irritation, and burning.

What's still unanswered

Long-term results, for one. The 2026 review called its own follow-up short. The individual trials stopped at 16 weeks, 120 days, or four months. The cited reports do not tell us what happened after participants stopped.

Several abstracts also left out contact time, dropout numbers, and funding, which limits how far you can push their conclusions.

Where a strength was stated, these studies tested 5%. My search found no record through August 16, 2026 that tested this finished 10% formula.

Next step

Read the linked abstracts and the research page. For a diagnosis, see a board-certified dermatologist, and get an in-person exam for any spot that's new, changing, bleeding, or painful.